NCT03773107View on ClinicalTrials.gov

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

January 3, 2019

Primary Completion Date

November 7, 2022

Study Completion Date

February 21, 2024

Conditions

Multiple Myeloma

Interventions

DRUG

Carfilzomib

Irreversible proteasome inhibitor

DRUG

Ruxolitinib

Oral JAK inhibitor

DRUG

Dexamethasone

glucocorticoid

Trial Locations (2)

28204

Levine Cancer Institute, Charlotte

48201

Karmanos Cancer Institute, Detroit

Sponsors

Collaborators (2)

Incyte Corporation

All Listed Sponsors

collaborator

Incyte Corporation

INDUSTRY

collaborator

Multiple Myeloma Research Consortium

NETWORK

collaborator

Amgen

INDUSTRY

lead

Wake Forest University Health Sciences

OTHER